Harvard Women's Health Watch

In the news: FDA approves the first oral drug for reducing multiple sclerosis relapses

People with relapsing forms of multiple sclerosis (MS) have a new option for reducing periodic attacks (relapses) and for delaying the progression of MS-related disability. MS is typically treated with injected drugs or infusions, which can be painful and inconvenient and may discourage some patients from staying on therapy. The FDA has approved the first oral medication, fingolimod, brand name Gilenya.
To continue reading this article, you must login.
  • Research health conditions
  • Check your symptoms
  • Prepare for a doctor's visit or test
  • Find the best treatments and procedures for you
  • Explore options for better nutrition and exercise
Learn more about the many benefits and features of joining Harvard Health Online »